Clinical Trials
22 trialsNCT06904235 2026-03-31
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Helsinn Healthcare SA
Phase 2 Recruiting
NCT04592198 2025-03-24
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Xiamen LP Pharmaceutical Co., Ltd
Phase 2 Completed
NCT05315999 2025-03-19
ProTreat
University Hospital Freiburg
Phase 2 Completed
NCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT05202275 2022-01-21
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
ChineseAMS
Phase 2 Unknown
NCT03097588 2021-07-12
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00900757 2019-08-28
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Duke University
Phase 2 Completed
NCT03960151 2019-05-22
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03862144 2019-03-05
GIM15-NEPA
Consorzio Oncotech
Phase 2 Completed
NCT00903396 2017-11-24
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00895245 2017-05-18
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
University of Washington
Phase 2 Terminated
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT00306735 2016-12-05
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Eisai Inc.
Phase 2 Completed
NCT02445872 2015-12-09
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Zhejiang University
Phase 2 Unknown
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT02290470 2014-11-14
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT00636805 2014-04-01
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
Duke University
Phase 2 Terminated
NCT01031498 2012-08-07
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01018758 2009-11-25
NHLPal
Gruppo Italiano Studio Linfomi
Phase 2 Completed
NCT00666783 2008-04-25
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
Xijing Hospital
Phase 2 Completed